Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma

Research in Veterinary Science

Volumn 83, Issue 2, 2007, Pages 210-216

  Lee, J Y ^a   Tanabe, S ^a   Shimohira, H ^a   Kobayashi, Y ^a   Oomachi, T ^b   Azuma, S ^a   Ogihara, K ^c   Inokuma, H ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b PATHOLAB   (Japan)

^c AZABU UNIVERSITY   (Japan)

Author keywords

COX 2; Dog; MRP; P gp; TCC

Indexed keywords

CYCLOOXYGENASE 2; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOG DISEASE; FISHER EXACT TEST; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANK SUM TEST; SCORING SYSTEM; TRANSITIONAL CELL CARCINOMA;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 2; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN;

CANIS FAMILIARIS;

EID: 34250810858     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2006.12.012     Document Type: Article

References (38)

1. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., and Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 3 (1986) 381-389
2. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., Siegert A., Reles A., Klosterhalfen B., and Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. The American Journal of Pathology 160 3 (2002) 893-903
3. Dungworth, D.L., Hauser, J., Hahn, F.F., Wilson, D.W., Haenichen, T., Harkema, J.R., 1999. Histological classification of tumors of the respiratory system of Domestic Animals, 2nd series, vol. VI. Armed Forces Institute of Pathology, Washington, DC, pp. 16-19.
4. Ferrandina G., Legge F., Ranelletti F.O., Zannoni G.F., Maggiano N., Evangelisti A., Mancuso S., Scambia G., and Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95 4 (2002) 801-807
5. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F., Maggiano N., Gessi M., Mancuso S., Ranelletti F.O., and Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Annals of Oncology 13 8 (2002) 1205-1211
6. Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M.M., and Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Research 58 21 (1998) 4823-4826
7. Gaffney D.K., Holden J., Zempolich K., Murphy K.J., Dicker A.P., and Dodson M. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. American Journal of Clinical Oncology 24 5 (2001) 443-446
8. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry 62 (1993) 385-427
9. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., and Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research 54 2 (1994) 357-361
10. Khan K.N., Knapp D.W., Denicola D.B., and Harris R.K. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. American Journal of Veterinary Research 61 5 (2000) 478-481
11. Khan K.N., Stanfield K.M., Trajkovic D., and Knapp D.W. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Veterinary Pathology 38 1 (2001) 116-119
12. Khan K.N., Venturini C.M., Bunch R.T., Brassard J.A., Koki A.T., Morris D.L., Trump B.F., Maziasz T.J., and Alden C.L. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicologic Pathology 26 5 (1998) 612-620
13. Kleiter M., Malarkey D.E., Ruslander D.E., and Thrall D.E. Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Veterinary Radiology & Ultrasound 45 3 (2004) 255-260
14. Knapp D.W., Glickman N.W., Widmer W.R., DeNicola D.B., Adams L.G., Kuczek T., Bonney P.L., DeGortari A.E., Han C., and Glickman L.T. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer chemotherapy and pharmacology 46 3 (2000) 221-226
15. Kruh G.D., Chan A., Myers K., Gaughan K., Miki T., and Aaronson S.A. Expression complementary DNA library transfer establishes MRP as a multidrug resistance gene. Cancer research 54 7 (1994) 1649-1652
16. Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.S., Khan K.N., Masferrer J.L., Woerner B.M., Snyder P.W., and Koki A.T. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Research 59 22 (1999) 5647-5650
17. Mutsaers A.J., Mohammed S.I., DeNicola D.B., Snyder P.W., Glickman N.W., Bennett P.F., de Gortari A.E., Bonney P.L., and Knapp D.W. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins, Leukotrienes, and Essential Fatty Acids 72 3 (2005) 181-186
18. Nasi M.L., and Castiglione M. Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?. Annals of Oncology 13 8 (2002) 1169-1171
19. Norris A.M., Laing E.J., Valli V.E., Withrow S.J., Macy D.W., Ogilvie G.K., Tomlinson J., McCaw D., Pidgeon G., and Jacobs R.M. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). Journal of Veterinary Internal Medicine 6 3 (1992) 145-153
20. Osborne C.A., Low D.G., Perman V., and Barnes D.M. Neoplasms of the canine and feline urinary bladder: incidence, etiologic factors, occurrence and pathologic features. American Journal of Veterinary Research 29 10 (1968) 2041-2055
21. Osuka K., Suzuki Y., Watanabe Y., Takayasu M., and Yoshida J. Inducible cyclooxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage. Stroke 29 6 (1998) 1219-1222
22. Patel V.A., Dunn M.J., and Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. The Journal of Biological Chemistry 277 41 (2002) 38915-38920
23. Raspollini M.R., Amunni G., Villanucci A., Boddi V., and Taddei G.L. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. International Journal of Gynecological Cancer 15 2 (2005) 255-260
24. Ratnasinghe D., Daschner P.J., Anver M.R., Kasprzak B.H., Taylor P.R., Yeh G.C., and Tangrea J.A. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Research 21 3C (2001) 2141-2147
25. Rocha T.A., Mauldin G.N., Patnaik A.K., and Bergman P.J. Prognostic factors in dogs with urinary bladder carcinoma. Journal of Veterinary Internal Medicine 14 5 (2000) 486-490
26. Sabichi A.L., and Lippman S.M. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Seminars in Oncology 31 2 Suppl 7 (2004) 36-44
27. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., and Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Research 55 17 (1995) 3785-3789
28. Seed M.P., Brown J.R., Freemantle C.N., Papworth J.L., Colville-Nash P.R., Willis D., Somerville K.W., Asculai S., and Willoughby D.A. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Research 57 9 (1997) 1625-1629
29. Slovak M.L., Ho J.P., Bhardwaj G., Kurz E.U., Deeley R.G., and Cole S.P. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Research 53 14 (1993) 3221-3225
30. Strafuss A.C., and Dean M.J. Neoplasms of the canine urinary bladder. Journal of the American Veterinary Medical Association 166 12 (1975) 1161-1163
31. Sumizawa T., Chuman Y., Sakamoto H., Iemura K., Almquist K.C., Deeley R.G., Cole S.P., and Akiyama S. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somatic Cell and Molecular Genetics 20 5 (1994) 423-435
32. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 3 (1995) 493-501
33. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America 94 7 (1997) 3336-3340
34. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 5 (1998) 705-716
35. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Japanese Journal of Cancer Research 79 3 (1988) 285-296
36. Withrow S.J., and MacEwen E.G. Tumor of the Urinary System. Small Animal Clinical Oncology. third ed. (2001), Saunders, Philadelphia, PA 490-495
37. Withrow S.J., and MacEwen E.G. Tumors of the urinary system. In: Knapp D.W. (Ed). Small Animal Clinical Oncology. third ed. (2001), Saunders, Philadelphia, PA 490-499
38. Zaman G.J., Versantvoort C.H., Smit J.J., Eijdems E.W., de Haas M., Smith A.J., Broxterman H.J., Mulder N.H., de Vries E.G., and Baas F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Research 53 8 (1993) 1747-1750